Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation (CGC) generates a steady flow of news as a cannabis-focused manufacturer with operations spanning medical and adult-use markets, branded products, and vaporization devices. The Canopy Growth news page on Stock Titan aggregates these disclosures so readers can follow how the company’s strategy, financing, and operations evolve over time.
Company news frequently covers financial performance and capital structure. Canopy Growth issues quarterly results releases that discuss cannabis and Storz & Bickel net revenue, segment performance in Canada and international markets, gross margins, operating loss, adjusted EBITDA, and free cash flow, along with commentary on cost management and balance sheet strength. The company also announces financing transactions, such as term loan agreements, prepayments on senior secured debt, convertible debenture exchanges, and at-the-market equity programs.
Another major category of news involves corporate transactions and governance. Canopy Growth has reported entering into an arrangement agreement to acquire MTL Cannabis Corp., detailing consideration, required approvals, and expected strategic benefits. It also publishes results of its annual general and special meetings, including director elections, auditor appointments, share consolidation authority, and advisory votes on executive compensation, as well as updates on board and executive appointments.
Product and market updates are a recurring theme. The company announces launches such as Claybourne Gassers liquid diamonds All-in-One vapes and Claybourne Frosted Flyers infused pre-roll variety packs in Canada, along with expansions of the Spectrum Therapeutics medical portfolio in Australia through new softgel formats. It also highlights operational moves like dedicating the DOJA facility in Kelowna to medical cultivation for Spectrum Therapeutics patients.
Investors and observers who monitor CGC news can use this page to track developments in Canopy Growth’s Canadian adult-use and medical businesses, its international medical operations in Europe and Australia, its indirect exposure to the U.S. THC market through Canopy USA, and its ongoing efforts to manage debt, liquidity, and governance matters. Bookmark this feed to review new press releases, transaction updates, and regulatory communications as they are published.
Canopy Growth (Nasdaq: CGC) said MTL Cannabis shareholders overwhelmingly approved Canopy’s acquisition plan at a Feb 17, 2026 special meeting.
The vote saw 99.97% approval of all MTL shares and ~89% turnout. Closing remains subject to customary conditions and is expected before the end of March 2026.
Canopy Growth (Nasdaq: CGC) reported Q3 FY2026 results for the three months ended December 31, 2025, showing improving fundamentals in Canada and narrowing losses.
Key highlights: consolidated net revenue of $75M, cannabis net revenue of $52M, adjusted EBITDA loss narrowed to $3M, net loss narrowed 49% YoY, cash and equivalents $371M, net cash position $146M. Acquisition of MTL Cannabis on track to close in the current quarter.
Canopy Growth (NASDAQ:CGC) will release third quarter fiscal 2026 financial results for the period ended December 31, 2025 before markets open on February 6, 2026. The company will host a live audio webcast with CEO Luc Mongeau and CFO Tom Stewart on February 6, 2026 at 10:00 AM ET to discuss results.
A live audio webcast will be available at the provided link, and a replay will remain accessible by webcast until 11:59 PM ET on May 7, 2026.
Canopy Growth (Nasdaq: CGC, TSX: WEED) announced a series of recapitalization transactions closing on or around January 8, 2026 that extend all outstanding debt maturities to at least January 2031 and are expected to leave the company with approximately C$425 million in cash. Key elements include a Term Loan providing net proceeds of US$150 million (aggregate principal ~US$162M) maturing Jan 2031 and an exchange of ~C$96.4M of debentures for C$55M of new convertible debentures due July 2031, C$10.5M cash, 9,493,670 common shares and 12,731,481 warrants. Transaction warrants and registration rights will be issued; customary fees, covenants and security on substantially all assets apply.
Canopy Growth (CGC) will acquire all issued and outstanding shares of MTL Cannabis in a transaction valued at approximately $125 million equity and $179 million TEV. Consideration is 0.32 Canopy Growth share plus $0.144 cash per MTL share, implying ~$0.91 per MTL share and a 45% premium to MTL’s 20-day VWAP as of December 12, 2025. MTL reported $84M TTM revenue, 51% gross margin (before fair value adjustments) and $11M operating cash flow for the trailing twelve months ended September 30, 2025. Canopy expects ~$10M of run-rate synergies within 18 months and closing is expected before end of February 2026, subject to court, shareholder and regulatory approvals.
Canopy Growth (Nasdaq: CGC) announced on December 4, 2025 the national launch of Claybourne Gassers, a new line of All‑in‑One (AIO) liquid diamond vapes in Canada. The collection includes three 0.95g SKUs — Infused Grape Gasolina (Indica), Infused Blue Dream (Sativa) and Infused Lemon Cherry G (Hybrid) — each with 92–98% THC, a digital display, variable voltage, anti‑burn/anti‑clog tech and a rechargeable USB‑C palm format. Canopy also launched Claybourne Frosted Flyers 8‑pack infused pre‑rolls (8x0.35g) with 33–36% THC. Products are available at licensed retail stores and select online retailers across Canada, including Spectrum Therapeutics for registered medical consumers.
Canopy Growth (Nasdaq: CGC) expanded its Spectrum Therapeutics medical portfolio in Australia by launching new softgel capsules available through authorized prescribers.
The new formats are Spectrum Yellow Cannabis Oil Softgels (CBD 20mg), Spectrum Red Cannabis Oil Softgels (THC 10mg), and Spectrum Blue Cannabis Oil Softgels (Balanced THC 2.5mg : CBD 3.75mg), which complement existing Spectrum oils and flower and other Tweed, 7ACRES, and TWD flower products in Australia.
Company leadership said the softgels increase patient and prescriber choice and support the growth of its international medical business in a maturing Australian market.
Canopy Growth (NASDAQ:CGC) reported Q2 FY2026 results for the quarter ended September 30, 2025, showing sequential and year‑over‑year improvement across several metrics.
Key highlights: consolidated net revenue $67MM (+6% YoY); cannabis revenue $51MM (+12% YoY); Canada adult‑use $24MM (+30% YoY); Canada medical $22MM (+17% YoY). Cash and cash equivalents were $298MM, exceeding debt by $70MM, resolving prior going‑concern doubts. Q2 operating loss improved to $17MM (‑63% YoY) and Adjusted EBITDA loss narrowed to $3MM. The company reported margin headwinds from lower international sales and inventory provisions but captured $21MM of annualized cost savings since March 1, 2025.
Canopy Growth (NASDAQ:CGC, TSX:WEED) will release its second quarter fiscal 2026 financial results for the period ended September 30, 2025 before markets open on November 7, 2025.
Management will host a live audio webcast with Luc Mongeau, CEO, and Tom Stewart, CFO on November 7, 2025 at 10:00 AM ET. A live webcast link and a replay accessible through February 5, 2026 at 11:59 PM ET are provided.
Canopy Growth (Nasdaq: CGC) reported voting results from its Annual General and Special Meeting reconvened on October 10, 2025. All matters in the company proxy were approved by the requisite votes.
Key items approved include election of all director nominees (each elected to serve until the next annual meeting), re-appointment of PKF O’Connor Davies as auditors for the fiscal year ending March 31, 2026, an advisory vote on named executive officer compensation, and an amendment authorizing a potential share consolidation that the board may implement within 12 months or let lapse.